# N4 Pharma excited by most comprehensive in vivo study to date

- Link: https://www.directorstalkinterviews.com/n4-pharma-excited-by-most-comprehensive-in-vivo-study-to-date/412859244
- Published: 2020-09-17T07:07:11+01:00
- Author: Giles Arbor

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for vaccines and cancer treatments, has announced its
unaudited interim results for the six months ended 30th June 2020.

**Highlights:**

·      Refined strategy to focus on three, clearly defined, work streams:

o  the optimisation of production and loading of Nuvec® as a delivery technology
platform for nucleic acid vaccines;

o  the Covid-19 proof of concept research programme; and

o  feasibility studies into Nuvec® for use in oral vaccines and other applications.

·      Successful transfection _in vitro_ of HEK 293T cells with Nuvec® loaded with
the Coronavirus DNA Plasmid

·      Move to full _in vivo_ study with the Coronavirus and other DNA plasmids 
with measurement of production of antibodies

·      Research Collaboration Agreement with Nanomerics Limited out of UCL’s School
of Pharmacy

·      Appointment of Ardena as technology transfer and manufacturing partner

·      Operating loss for the period was £585,066 (30 June 2019: £552,160)

·      Placing of 50,731,250 new Ordinary Shares to raise c.£2 million

·      Issue of a further 3,886,562 new Ordinary Shares following warrant and option
exercises raising £139,262.48

·      Cash balance at period end of approximately £2.44 million

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:** 
> “The arrival of the Covid-19 pandemic during the period has thrown up considerable
> challenges globally but also opportunities. Whilst continuing with our optimisation
> work of Nuvec® as a delivery platform technology, the immediate need to address
> the threat of Covid-19 encouraged us to look at more specific, product driven,
> applications resulting in our proof of concept work with Nuvec® loaded with the
> Coronavirus DNA Plasmid. Our subsequent _in vitro_ success was extremely pleasing
> but to maximise our chances of success in any full _in vivo_ study we now need
> to incorporate the findings of our optimisation work. This is key as we look to
> further our work with the Coronavirus plasmid in parallel to working with more
> generic DNA plasmids which may be more applicable in collaborations on multiple
> other vaccines. To that end, we are excited to be moving towards our most comprehensive
> _in vivo_ study to date and are in the process of scoping the different aspects
> of the study.
> “At the same time, we aim to maximise the potential uses of Nuvec® as we continue
> to look at other applications including assessing its ability for use in the delivery
> of vaccines orally.  We remain fully funded for the current work programmes and
> I look forward to providing further updates in due course.”

Share on:
